This pathway approach revealed that 1) 13 proteins were conserved, whereas five lacked data sufficient to determine specific critical amino acids; 2) variation in protein-protein interfaces is ...

SOUTH SAN FRANCISCO, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that Sean ...

Disclaimer: AlphaGalileo is not responsible for the accuracy of news releases posted to AlphaGalileo by contributing institutions or for the use of any information through the AlphaGalileo system.

Imatinib oral solution has gained FDA approval for the treatment of some cancers, including certain forms of leukemia.

FDA Project Team supports the company’s proposed Phase 3 trial strategy, including overall trial design, target patient population, treatment ...

What they found was impairment of immune cells, particularly T cells, in children with MIS-C and severe bacterial infection, ...

A relatively easy way to encourage your Black patients with MS to participate in clinical research is to introduce them to ...

I am proposing that all companies currently engaged in developing biosimilars join hands with their regulatory and scientific ...

At The Liver Meeting 2024, Arbutus Biopharma Corp. presented data from the phase IIa Im-prove study showing its RNAi drug, imdusiran, in combination with pegylated interferon alfa-2α and nucleos(t)ide ...

On Friday, Vir Biotechnology, Inc. (NASDAQ:VIR) announced end-of-treatment data from Part B of the MARCH Phase 2 study ...

Arbutus Biopharma Corporation (NASDAQ: ABUS) has announced new data from its im-Prove I Phase 2a clinical trial (AB-729-201) showing significant progress in achieving a functional cure for patients ...